Published in J Clin Oncol on November 05, 2007
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol (2013) 4.19
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood (2015) 3.47
How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood (2009) 2.86
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood (2011) 2.34
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol (2014) 2.33
Update on therapy of chronic lymphocytic leukemia. J Clin Oncol (2011) 2.19
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol (2012) 1.98
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol (2010) 1.77
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood (2014) 1.75
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood (2009) 1.75
How I treat CLL up front. Blood (2009) 1.71
Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood (2012) 1.41
Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer (2010) 1.40
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol (2013) 1.38
Have we forgotten the purpose of phase III studies? J Clin Oncol (2007) 1.38
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood (2010) 1.34
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol (2013) 1.34
Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia (2009) 1.30
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer (2008) 1.29
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood (2009) 1.25
Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica (2013) 1.17
Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol (2010) 1.16
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol (2010) 1.13
Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol (2012) 1.12
Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag (2009) 1.12
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res (2009) 1.10
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood (2011) 1.07
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med (2014) 1.02
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica (2014) 1.00
Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol (2012) 0.98
Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98
New antibody approaches to lymphoma therapy. J Hematol Oncol (2014) 0.97
New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia. ISRN Oncol (2013) 0.96
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer (2011) 0.95
MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget (2012) 0.95
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol (2009) 0.95
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia (2013) 0.92
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer (2010) 0.92
Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica (2013) 0.91
Initial treatment of CLL: integrating biology and functional status. Blood (2015) 0.90
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood (2015) 0.89
Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol (2010) 0.88
Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther Clin Risk Manag (2010) 0.88
Adaptive immunity in cancer immunology and therapeutics. Ecancermedicalscience (2014) 0.87
Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies. Curr Hematol Malig Rep (2013) 0.86
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res (2013) 0.86
Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest (2009) 0.85
VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis (2013) 0.84
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer Med (2014) 0.84
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer (2010) 0.83
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica (2008) 0.83
Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol (2012) 0.82
Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother (2012) 0.82
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.81
Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. Clin Dev Immunol (2011) 0.81
The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica (2014) 0.81
The clinical significance of patients' sex in chronic lymphocytic leukemia. Haematologica (2014) 0.80
Practical approach to management of chronic lymphocytic leukemia. Arch Med Sci (2015) 0.80
Infectious complications in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis (2012) 0.80
Targeted treatment for chronic lymphocytic leukemia. Onco Targets Ther (2011) 0.79
Advances in treating chronic lymphocytic leukemia. F1000Prime Rep (2014) 0.79
Recent advances in the treatment of follicular lymphoma. Int J Clin Oncol (2009) 0.79
Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia. PLoS One (2013) 0.78
A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery. MAbs (2011) 0.78
New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab. Ther Clin Risk Manag (2015) 0.77
Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia. Am J Clin Pathol (2013) 0.77
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther (2010) 0.77
Monoclonal antibody therapy and renal transplantation: focus on adverse effects. Toxins (Basel) (2014) 0.77
Personalized medicine in CLL: current status and future perspectives. Cancer Lett (2013) 0.76
Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev Anticancer Ther (2011) 0.76
Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol (2015) 0.76
Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. J Clin Oncol (2017) 0.75
Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies? Hematol Oncol Clin North Am (2014) 0.75
Alemtuzumab in the up-front setting. Ther Clin Risk Manag (2008) 0.75
Chemotherapy: New FluCam combination therapy has familiar limitations. Nat Rev Clin Oncol (2011) 0.75
Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting. Rambam Maimonides Med J (2014) 0.75
A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia. Adv Ther (2016) 0.75
Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia? J Clin Oncol (2008) 0.75
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Clin Interv Aging (2015) 0.75
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leuk Lymphoma (2013) 0.75
Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis. Clinicoecon Outcomes Res (2014) 0.75
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). J Blood Med (2010) 0.75
Application of new drugs in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis (2010) 0.75
Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Rev Bras Hematol Hemoter (2016) 0.75
Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. Onco Targets Ther (2015) 0.75
Alemtuzumab-induced elimination of HIV-1-infected immune cells. J Virus Erad (2016) 0.75
Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. Biologics (2015) 0.75
Targeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells. Exp Hematol Oncol (2014) 0.75
Chlorambucil-induced acute interstitial pneumonitis. Case Rep Hematol (2014) 0.75
The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies. J Blood Med (2010) 0.75
Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia. Cancer Manag Res (2011) 0.75
Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data. Ther Adv Hematol (2016) 0.75
Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol (2012) 0.75
Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. Ther Adv Hematol (2014) 0.75
Precision spherical nucleic acids for delivery of anticancer drugs. Chem Sci (2017) 0.75
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2010) 9.77
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol (2009) 3.91
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2011) 3.71
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol (2008) 3.49
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood (2007) 3.15
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol (2010) 2.51
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 2.33
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood (2008) 2.17
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 2.15
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol (2011) 1.81
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol (2013) 1.60
Role of angiogenesis in chronic lymphocytic leukemia. Cancer (2006) 1.60
Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma (2008) 1.58
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol (2012) 1.56
Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma (2011) 1.50
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol (2012) 1.50
Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma (2009) 1.44
MicroRNA biogenesis, functionality and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2006) 1.43
Intracoronary administration of stem cells in patients with acute myocardial infarction - angiographic follow-up. Kardiol Pol (2009) 1.42
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma (2006) 1.42
The persistence of t(14;18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for 'a lymphoma stem cell'. Leuk Lymphoma (2009) 1.42
IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. Leuk Lymphoma (2010) 1.42
MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma (2009) 1.41
Individual differences in the effectiveness of intracoronary bone marrow cell transplantation assessed by gated sestamibi SPECT/FDG PET imaging. J Nucl Cardiol (2008) 1.41
Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol (2011) 1.39
Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia. Leuk Lymphoma (2014) 1.39
MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood (2011) 1.32
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood (2009) 1.28
Targeted drugs in chronic myeloid leukemia. Curr Med Chem (2008) 1.25
Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol (2004) 1.25
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol (2009) 1.24
The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett (2005) 1.22
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol (2014) 1.22
Difficulties in using 1,3-{beta}-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies--high frequency of false-positive results and their analysis. J Med Microbiol (2010) 1.21
Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma (2007) 1.19
Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood (2002) 1.18
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood (2005) 1.18
Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology (2004) 1.14
MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood (2012) 1.11
High-resolution human leukocyte antigen allele and haplotype frequencies of the Polish population based on 20,653 stem cell donors. Hum Immunol (2011) 1.11
Real-time PCR diagnostics failure caused by nucleotide variability within exon 4 of the human cytomegalovirus major immediate-early gene. J Clin Microbiol (2007) 1.11
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood (2012) 1.11
Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep (2008) 1.10
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol (2012) 1.10
Idiopathic systemic capillary leak syndrome misdiagnosed and treated as polycythemia vera. Acta Haematol (2005) 1.09
Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw (2006) 1.09
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol (2011) 1.07
The number and distribution of blood dendritic cells in the epidermis and dermis of healthy human subjects. Folia Histochem Cytobiol (2006) 1.03
Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer (2010) 1.03
Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica (2013) 1.02
Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction. Am J Cardiol (2009) 1.01
Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <or=50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica (2004) 1.01
Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett (2008) 1.00
Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol (2008) 1.00
Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm (2003) 1.00
Intravenous PLASMA-LYTE as a major cause of false-positive results of platelia Aspergillus test for galactomannan detection in serum. J Clin Microbiol (2007) 0.99
The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer (2013) 0.98
How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk (2011) 0.98
Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biol Blood Marrow Transplant (2012) 0.97
Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. Br J Haematol (2011) 0.97
Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses (2012) 0.96
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol (2012) 0.96
ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. Haematologica (2013) 0.95
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood (2013) 0.95
Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev (2013) 0.95
Geographical prevalence and risk factors for pterygium: a systematic review and meta-analysis. BMJ Open (2013) 0.95
Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz) (2010) 0.94
Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. Leuk Lymphoma (2011) 0.94
Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood (2010) 0.93
Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol (2010) 0.93